GLSI - NASDAQ

Greenwich LifeSciences, Inc.

GLSI·NASDAQ

$24.29

-15%

HealthcareBiotechnology

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$356.53M

EPS-1.4300

P/E Ratio-16.99

Earnings Date06/02/2026

-6.74M

Assets

-265%

3Y-150.0%

5Y-123.0%

10Y-24963.0%

2.02M

Total Liabilities

29%

3Y+667.0%

5Y+93.0%

10Y-76.0%

1.79M

Total Equity

-29%

3Y-86.0%

5Y-94.0%

10Y-121.0%

Greenwich LifeSciences, Inc. Funding & Solvency Profile

GLSI · NASDAQ

Current Assets

Cash & Cash Equivalents-6.74M

Net Receivables0.00

Inventory0.00

Other Current Assets0.00

Total Current Assets-6738796

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets0

Total Assets

-6.74M

Financial Health Analysis

Working Capital

-6738796

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

0% Current

Greenwich LifeSciences, Inc. Balance Sheet

GLSI • NASDAQ

Greenwich LifeSciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	-6.7M	4.1M	7M	13.5M	27.2M	28.7M	6.8K	85.1K	54.0
Cash & Short-Term Investments	-6.7M	4.1M	7M	13.5M	27.2M	28.7M	6.8K	85.1K	54.0
Total Current Assets	-6.7M	4.1M	7M	13.5M	27.2M	28.7M	6.8K	85.1K	54.0
NON-CURRENT ASSETS
Intangible Assets	0.0	1.8K	5.4K	9K	12.6K	16.2K	19.8K	23.4K	0.0
Goodwill & Intangible Assets	0.0	1.8K	5.4K	9K	12.6K	16.2K	19.8K	23.4K	0.0
Total Non-Current Assets	0.0	1.8K	5.4K	9K	12.6K	16.2K	19.8K	23.4K	27.1K
Total Assets	-6.7M	4.1M	7M	13.5M	27.2M	28.7M	26.7K	108.5K	27.1K
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	1.2M	35.5K	0.0	0.0	711K	635.2K	277.6K	161.1K
Accounts Payable	0.0	1.2M	35.5K	0.0	0.0	711K	635.2K	277.6K	161.1K
Accrued Expenses	0.0	0.0	258.9K	262.9K	385.2K	59.4K	11.6K	30.9K	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	275.2K	635.2K	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	-635.0	-420.2K	0.0
Other Current Liabilities	0.0	382.2K	0.0	0.0	0.0	0.0	95.8K	420.2K	396.4K
Total Current Liabilities	0.0	1.6M	294.4K	262.9K	385.2K	1M	1.4M	728.6K	557.5K
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.5M	8M
Total Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.5M	8M
Total Liabilities	2M	1.6M	294.4K	262.9K	385.2K	1M	1.4M	10.2M	8.6M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	2K	2K	5.2K
Common Stock	0.0	13.2K	12.8K	12.8K	13.1K	12.7K	8.5K	203.0	542.0
Additional Paid-In Capital	0.0	68.7M	57.1M	54.7M	60.5M	56.7M	25.9M	13.7M	0.0
Retained Earnings	0.0	-66.2M	-50.4M	-41.5M	-33.6M	-29.1M	-27.2M	-23.8M	-22.1M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-541.0
Other Total Stockholders' Equity	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.6M
Total Stockholders' Equity	1.8M	2.5M	6.7M	13.2M	26.8M	27.6M	-1.4M	-10.1M	-8.5M
Total Equity	1.8M	2.5M	6.7M	13.2M	26.8M	27.6M	-1.4M	-10.1M	-8.5M
SUMMARY
Total Liabilities & Equity	3.8M	4.1M	7M	13.5M	27.2M	28.7M	26.7K	108.5K	27.1K
Total Debt	0.0	0.0	0.0	0.0	0.0	275.2K	635.2K	420.2K	0.0
Net Debt	6.7M	-4.1M	-7M	-13.5M	-27.2M	-28.4M	-6.2K	335.1K	-54.0
Shares Outstanding	13,630,257	13,630,257	13,630,257	13,630,257	13,630,257	13,630,257	13,630,257	13,630,257	13,630,257

SEC Filings

GLSI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	June 04, 2026	March 31, 2026	2026	View Filing
10-K 10-K 2025 FY FY	June 01, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 18, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing
DEF 14A DEF 14A 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 14, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 24, 2025	July 19, 2025	2025	View Filing
10-Q 10-Q 2025 Q1 Q1	May 20, 2025	March 31, 2025	2025	View Filing
10-K 10-K 2024 FY FY	April 15, 2025	December 31, 2024	2024	View Filing
8-K 8-K 2024 N/A	December 19, 2024	December 19, 2024	2024	View Filing

Showing 1 to 10 of 69 filings

Related Guides

Blog Categories

Continue your GLSI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.